GSK lung-cancer treatment suffers Phase III setback

GlaxoSmithKline's (GSK -1.8% in London) MAGE-A3 lung-cancer immunotherapeutic failed to meet two out of three primary goals in a Phase III trial.

The therapy didn't significantly boost disease-free survival in non-small cell lung cancer patients vs a placebo in either the overall MAGE-A3 positive population or in MAGE-A3-positive patients who did not receive chemotherapy.

MAGE-A3 is a tumor-specific antigen found in cancer but not in normal cells.

GSK will continue the trial to assess the third primary endpoint, which is designed to identify a subset of MAGE-A3 positive patients that may benefit from the treatment. (PR)

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs